Literature DB >> 23884797

Role of visual evoked potentials in the assessment and management of optic pathway gliomas in children.

C Van Mierlo1, W Spileers, E Legius, I Casteels, C Cassiman.   

Abstract

OBJECTIVE: The aim of this study is to investigate the role of pattern reversal visual evoked potentials (pVEPs) in the screening and monitoring of optic pathway gliomas (OPGs) in children with and without neurofibromatosis type 1.
METHODS: A review of the English literature published between 1980 and 2012 was performed, with comparison of results of retro- and prospective studies.
RESULTS: Pattern reversal VEPs have a high sensitivity (85.7-100 %) for the diagnosis of OPGs, moreover they are safe and cost-effective. Conversely, they have a low specificity (43-83 %) and are not widely available. Besides, pattern reversal VEP results can be unreliable in young children, because of the need for a good cooperation. The studies that were analyzed have drawbacks, including the small sample size, the retrospective design, the differences in gold standard for diagnosis, the different interpretation of small changes in VEP results and the lack of control groups.
CONCLUSION: There is still debate about the gold standard for the screening and follow-up of OPGs. The added value of pVEPs to the ophthalmic examination is controversial. Randomized controlled trials or prospective multicentre studies are necessary to assess with sufficient accuracy the sensitivity and specificity of pattern reversal VEPs in the screening for OPGs and its follow-up.

Entities:  

Mesh:

Year:  2013        PMID: 23884797     DOI: 10.1007/s10633-013-9399-5

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  51 in total

1.  Pattern ERG and VEP maturation in schoolchildren.

Authors:  Jelka Brecelj; M Strucl; I Zidar; M Tekavcic-Pompe
Journal:  Clin Neurophysiol       Date:  2002-11       Impact factor: 3.708

2.  Can screening for optic nerve gliomas in patients with neurofibromatosis type I be performed with visual-evoked potential testing?

Authors:  Darcy H Wolsey; Scott A Larson; Donnel Creel; Robert Hoffman
Journal:  J AAPOS       Date:  2006-08       Impact factor: 1.220

3.  Optic gliomas in neurofibromatosis type 1: role of visual evoked potentials.

Authors:  G T Liu; P Malloy; M Needle; P Phillips
Journal:  Pediatr Neurol       Date:  1995-01       Impact factor: 3.372

Review 4.  Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas.

Authors:  Frederic G Dhermain; Peter Hau; Heinrich Lanfermann; Andreas H Jacobs; Martin J van den Bent
Journal:  Lancet Neurol       Date:  2010-08-10       Impact factor: 44.182

Review 5.  Electrophysiological assessment of visual pathway function in infants.

Authors:  A Kriss; I Russell-Eggitt
Journal:  Eye (Lond)       Date:  1992       Impact factor: 3.775

6.  Electrophysiological findings in neurofibromatosis type 1.

Authors:  Deniz Yerdelen; Filiz Koc; Murat Durdu; Mehmet Karakas
Journal:  J Neurol Sci       Date:  2011-04-17       Impact factor: 3.181

Review 7.  Intracranial gliomas in neurofibromatosis type 1.

Authors:  R Listernick; J Charrow; D H Gutmann
Journal:  Am J Med Genet       Date:  1999-03-26

Review 8.  Optic pathway gliomas: a review.

Authors:  Mandy J Binning; James K Liu; John R W Kestle; Douglas L Brockmeyer; Marion L Walker
Journal:  Neurosurg Focus       Date:  2007       Impact factor: 4.047

Review 9.  Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications.

Authors:  Mohammed F Shamji; Brien G Benoit
Journal:  Neurosurg Focus       Date:  2007       Impact factor: 4.047

Review 10.  Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients.

Authors:  Sureka Thiagalingam; Maree Flaherty; Frank Billson; Kathryn North
Journal:  Ophthalmology       Date:  2004-03       Impact factor: 12.079

View more
  7 in total

Review 1.  Optical coherence tomography as a marker of vision in children with optic pathway gliomas.

Authors:  Ana Banc; Cristina Stan; Ioan Stefan Florian
Journal:  Childs Nerv Syst       Date:  2017-08-26       Impact factor: 1.475

2.  Central and peripheral steady-state visual evoked potentials in children with optic pathway gliomas.

Authors:  Sarah Zakaib Rassi; Luis H Ospina; Ariane Bochereau; Yvan Samson; Sébastien Perreault; Dave Saint-Amour
Journal:  Doc Ophthalmol       Date:  2019-06-26       Impact factor: 2.379

Review 3.  Visual electrophysiology in the clinical evaluation of optic neuritis, chiasmal tumours, achiasmia, and ocular albinism: an overview.

Authors:  Jelka Brecelj
Journal:  Doc Ophthalmol       Date:  2014-06-25       Impact factor: 2.379

4.  Visual function assessed by visually evoked potentials in optic pathway low-grade gliomas with and without neurofibromatosis type 1.

Authors:  Patrícia de Freitas Dotto; Adriana Berezovsky; Andrea Maria Cappellano; Nasjla Saba da Silva; Paula Yuri Sacai; Frederico Adolfo B Silva; Arthur Gustavo Fernandes; Daniel Martins Rocha; Solange Rios Salomão
Journal:  Doc Ophthalmol       Date:  2018-05-15       Impact factor: 2.379

5.  Assessment of Central Retinal Sensitivity Employing Two Types of Microperimetry Devices.

Authors:  Hongting Liu; Millena G Bittencourt; Jiangxia Wang; Raafay Sophie; Rachel Annam; Mohamed A Ibrahim; Yasir J Sepah; Ahmadreza Moradi; Hendrik P N Scholl; Quan Dong Nguyen
Journal:  Transl Vis Sci Technol       Date:  2014-09-12       Impact factor: 3.283

6.  Detection and characterisation of visual field defects using Saccadic Vector Optokinetic Perimetry in children with brain tumours.

Authors:  Ian C Murray; Conrad Schmoll; Antonios Perperidis; Harry M Brash; Alice D McTrusty; Lorraine A Cameron; Alastair G Wilkinson; Alan O Mulvihill; Brian W Fleck; Robert A Minns
Journal:  Eye (Lond)       Date:  2018-06-07       Impact factor: 3.775

Review 7.  Clinical electrophysiology of the optic nerve and retinal ganglion cells.

Authors:  Oliver R Marmoy; Suresh Viswanathan
Journal:  Eye (Lond)       Date:  2021-06-11       Impact factor: 3.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.